Mersana Therapeutics, Inc

Add to watchlist
€12.3
Last updated:06/09/2021
0M4: F
Mersana Therapeutics, Inc

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development of antibody drug conjugates (ADC) for cancer patients with unmet need. The company develops XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatme… Show more

P/E ratio
-

Stock volatility (Beta)
past 12 months

Become our supporter to unlock all data!
Company results
Quarterly
Annual
Fundamentals
2017
2018
2019
2020
Net Income
Income minus expenses, depreciation, interest, taxes, and other expenses
-38.707M
-64.257M
-66.01%
-28.208M
+56.10%
-88.045M
-212.13%
Cashflow
Sum up money going in and out company
-42.679M
-55.216M
-29.38%
-67.744M
-22.69%
-74.696M
-10.26%
Total liabilities
All combined debts and obligations
60.721M
69.707M
+14.80%
29.223M
-58.08%
45.312M
+55.06%
Company profile
CEO
Ms. Anna Protopapas
Market capitalization
Small (0.87B)